CRSP - Stock Analysis & Overview

About CRISPR Therapeutics AG

Biotechnology

Healthcare

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases...

CRISPR Therapeutics AG Key Metrics

Market Cap: $4B
52 Weeks Low: $43.42
52 Weeks High: $91.10
P/B: 2.10x
P/E: -17.03x
P/S: 20.27x

Upcoming Events

CRSP Analyst Forecasts

‌

CRSP Financials

CRSP Income Statement Key Metrics

Revenue(TTM)201.62 M
Gross Profit(TTM)61.70 M
EBITDA(TTM)-317.82 M
Net Income(TTM)-239.59 M
EPS Diluted(TTM)-2.8299999999999996

Decode CRSP's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

CRSP earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of CRSP (0.648) is lower than the average of its peers (0.819).

Net Profit Margin vs Peers

Net profit margin ratio of CRSP (-0.415) is higher than the average of its peers (-3.764).

CRSP Return on Equity

See how efficiently CRSP generates profit for it's shareholders.

-8.16%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of CRSP (-0.082) is higher than the average of its peers (-0.175).

Return on Equity Growth

CRSP's Return on Equity has grown significantly over the past 10 years, increasing by over 21.81%.

CRSP Revenue Growth

See how CRSP has grown it's revenue over the past 10 years.

‌

Revenue Growth

CRSP's revenue has grown significantly over the past 10 years, increasing by over 0%.

CRISPR Therapeutics AG

Page title

Section title